Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
Tools
Tools
Tools
Abed, A., Khattak, A., Millward, M., Chopra, A. and Gray, E. (2019) Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy. Asia-Pacific Journal of Clinical Oncology, 15 (S9). pp. 161-162.
Link to Published Version: https://doi.org/10.1111/ajco.13263
*Subscription may be required
*Subscription may be required
Abstract
Background: We aimed to assess the role of genomic HLA‐I/II heterozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non‐small lung cancer treated by PD1/L1 inhibitors...
| Item Type: | Journal Article |
|---|---|
| Murdoch Affiliation(s): | Institute for Immunology and Infectious Diseases |
| Publisher: | John Wiley and Sons |
| Copyright: | © 2019 John Wiley & Sons Australia, Ltd. |
| Other Information: | Special Issue: COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, 12–14 November 2019, Adelaide Convention Centre, South Australia |
| URI: | http://researchrepository.murdoch.edu.au/id/eprint/53129 |
 |
Item Control Page |